Higher levels of proteins called chaperones are linked with lower levels of disease-driving toxic protein clumps in the brains of people with Parkinson’s disease, a new study shows. The findings suggest that increasing chaperone proteins may be a viable therapeutic strategy for Parkinson’s. Data from the study also revealed…
News
Researchers have developed a method to detect clumps of alpha-synuclein protein, a hallmark of Parkinson’s disease, within extracellular vesicles (EVs) purified from blood, providing a possible aid to Parkinson’s diagnosis before symptoms appear. EVs are tiny membrane-bound sacs released from cells that can carry a variety of molecules, including…
People who received five or more courses of penicillin antibiotic treatment in the five years before a Parkinson’s diagnosis had an approximately 15% lower risk of developing the disease than those who took no antibiotics, according to a Rutgers Health study. Conversely, treatment with two or more courses of…
The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…
Lianna Genovese, the 25-year-old founder of Imaginable Solutions and the inventor of Guided Hands, a device that helps individuals with limited hand mobility, was recognized with the 2024 Muhammad Ali Humanitarian Award. Various conditions can limit a person’s ability to write, draw, dress themselves, or use technology, including…
Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a brain electrode-guided tool for use in neurological brain surgeries, including those for Parkinson’s disease. “As the world’s first FDA [U.S. Food and Drug Administration] cleared system for both diagnostic…
Side-to-side eye movements can help reduce body sway and improve postural stability in people with Parkinson’s disease, even though Parkinson’s patients generally have difficulty coordinating their eye movements, a new study reports. The study, “People with Parkinson’s Disease Are Able to Couple Eye Movements and Postural…
A type of RNA structure called G-quadruplex, or G4 — a four-stranded RNA structure that forms when calcium enters cells in response to stress — may offer a scaffold for the alpha-synuclein protein to clump together and become toxic to nerve cells in Parkinson’s disease, research suggests. In a…
Sunbird Bio’s blood test to indirectly detect toxic clumps of alpha-synuclein protein in the brain, a hallmark of Parkinson’s disease, may help yield an accurate Parkinson’s diagnosis, according to data from a clinical study. The company presented the results in a poster, “Using neural derived EV-bound biomarkers in…
The U.S. Food and Drug Administration (FDA) has set Feb. 1, 2025, as a goal date for deciding whether to approve SPN-830, an apomorphine infusion pump, for the continuous treatment of off episodes in Parkinson’s disease. That’s according to a financial update from the device’s developer,…
Recent Posts
- It’s time to ban paraquat, an herbicide linked to increased Parkinson’s risk
- Caregiving is also about bringing back some of what Parkinson’s takes away
- Gut protein misfolding may spot Parkinson’s years before symptoms
- I wish I could take my husband’s pain away
- Toxic protein clumps damage brain blood vessels in Parkinson’s: Study